There are many reasons why we’re seeing little effort in the clinical development of new antibiotics to treat gonorrhea. As I’ve mentoned elsewhere, this bacteria is beginning to become resistant to the older antibiotics like ciprofloxacin or azithromycin, and we’re left only with the injectable ceftriaxone. Here you can find a nice summary that explains why a large part of the problem rests with the pharmacuetical industry, who sees any investment in the development of new antibiotics expensive with poor economic return. Also any future use would undoubtedly be strictly vetted and controlled by the health authories.